EnteroBiotix Ltd news
Our Founder & CEO Dr James McIlroy was recently featured on The Pharma Letter podcast with Simon Wentworth discussing mastering the microbiome.
James discusses how EnteroBiotix is developing its pipeline of highly diverse microbiome enhancing therapeutics through a unique approach to development and manufacturing, focussed on supply chain control and novel technologies.
Listen here to learn more about the future of modern medicine and
EnteroBiotix, a biopharmaceutical company developing novel highly-diverse microbial therapeutics that enhance the gut microbiome, today announced the mechanical completion of a new purpose built world-class facility at Strathclyde Business Park, Glasgow, for manufacturing and quality control of its high-diversity microbial therapeutics, and an expansion of its corporate offices to support an increased headcount. This expansion follows the company’s successful $21.5M
EnteroBiotix, a Scottish biopharma focused on making gut microbiome therapies, said construction of its new manufacturing, lab and office facility has been completed.
Located at the Strathclyde Business Park in Bellshill, the 20,000-square-foot facility is designed to meet regulatory biologics requirements and product analysis while providing the company end-to-end control of its supply chain, the company said in a release.
The debut comes
EnteroBiotix, a biopharmaceutical company developing novel high-diversity microbial therapeutics that enhance the gut microbiome and target multiple indications, today announced the final closing of its oversubscribed USD $21.5 million (UK £15.5m) Series A financing. The proceeds will be used to further advance the company’s microbiome drug pipeline and underpin its product development and manufacturing capabilities.
The financing was led by Thairm Bio (Thairm) and inc